Home › Compare › FLYLF vs ABBV
FLYLF yields 825.08% · ABBV yields 3.06%● Live data
📍 FLYLF pulled ahead of the other in Year 1
Combined, FLYLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FLYLF + ABBV for your $10,000?
FLYHT Aerospace Solutions Ltd. provides real-time communications with aircrafts for the aerospace industry. It offers AFIRS, an automated flight information reporting system that is a satcom aircraft interface device, which enables real-time streaming of flight information, cockpit voice, and black box data streaming; TAMDAR, a tropospheric airborne meteorological data reporting system that aggregates and streams airborne weather data in real-time; AirMap, which provides real-time monitoring and insight of fleets; and UpTime, a ground-based, enterprise server that communicates with AFIRS through satellite connectivity and serves its customers with real-time applications. The company also offers FLYHTStream, a technology that performs real-time triggered alerting and black-box data streaming in the event of an abnormal situation in aircraft; FLYHTLog, which enables operators to monitor the status of their aircraft and have detailed out, off, on, and in time information; FLYHTVoice, a private communication channel for flight deck; and FLYHTMail, a two-way text messaging system for the flight crew and dispatch personnel. In addition, it provides aircraft health monitoring and automated engine trend reporting systems; and FLYHT Weather Observations that offers real-time weather data. It serves in the United States, Mexico, Asia, China, the Middle East, Canada, Australia, Africa, Europe, and South/Central America. The company was formerly known as AeroMechanical Services Ltd. and changed its name to FLYHT Aerospace Solutions Ltd. in May 2012. FLYHT Aerospace Solutions Ltd. was founded in 1998 and is headquartered in Calgary, Canada.
Full FLYLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.